Smallpox Vaccines

Vaccinia virus is the live poxvirus that was used as the smallpox vaccine. The development of this vaccine was an important step in the successful eradication of smallpox, an infection characterized by fever, rash and constitutional symptoms, with a high rate of morbidity and mortality. Attempts at control of smallpox began after it was noted that accidental exposure to smallpox by a scratch on the skin reduced the severity of infection. This led to the practice of “variolation”, which involved intentional administration of pustular fluids from smallpox scabs to uninfected persons. The practice of variolation began in China and India in the tenth century; deaths were reported as a complication of this procedure. The origins of vaccinia virus are uncertain. Successful vaccination was highly protective for development of any disease for five years and could protect from death or severe smallpox for up to 20 years. Periodic revaccination was necessary for optimal protection.

  • Generalized vaccinia
  • Eczema vaccinatum
  • Progressive vaccinia
  • Roseola vaccinia
  • Multiplicity reactivation
  • Vaccinia & aberrant infections
  • Vaccinia virus

Related Conference of Smallpox Vaccines

February 27-28, 2025

8th International Conference on Vaccines and Immunology

Paris, France
April 28-29, 2025

2nd Global Summit on Vaccines & Emerging Diseases

Bali, Indonesia
July 28-29, 2025

43rd Euro Global Summit and Expo on Vaccines & Vaccination

Aix-en-Provence, France
September 18-19, 2025

7th World Congress on Vaccine and Immunology

Amsterdam, Netherlands

Smallpox Vaccines Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in